Duncan McHale's most recent trade in Evelo Biosciences Inc was a trade of 6,500 Restricted Stock Units done . Disclosure was reported to the exchange on Aug. 7, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,500 | 13,000 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2023 | 6,500 | 11,375 (0%) | 0% | - | Common Stock | |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 07 Aug 2023 | 3,434 | 7,941 (0%) | 0% | 9.5 | 32,657 | Common Stock |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.13 per share. | 08 May 2023 | 66,730 | 97,516 (0%) | 0% | 0.1 | 8,375 | Common Stock |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 130,000 | 390,000 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 130,000 | 164,246 (0%) | 0% | - | Common Stock | |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 520,000 | 520,000 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 27 May 2022 | 34,246 | 34,246 (0%) | 0% | 1.5 | 49,999 | Common Stock |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Evelo Biosciences Inc | Duncan McHale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 96,500 | 96,500 | - | - | Stock Option (Right to Buy) |